Search
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnDexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: (+)-(S)-p-isobutylhydratropic acidAzelnidipine
go.drugbank.com/drugs/DB09230InvestigationalAzelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLacidipine
go.drugbank.com/drugs/DB09236ApprovedLacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia . It displays specificity in the vascular smoo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLevamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigationalLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesManidipine
go.drugbank.com/drugs/DB09238ApprovedInvestigationalWithdrawnManidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsNiguldipine
go.drugbank.com/drugs/DB09239ExperimentalNiguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesNiludipine
go.drugbank.com/drugs/DB09240ExperimentalNiludipine is a calcium channel blocker.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalLumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused ...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducersOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung canc...
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesInsulin beef
go.drugbank.com/drugs/DB09456ApprovedInsulin beef has been discontinued in the US and Canada since 2017.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers